Galiya S. Nuralieva

Galiya S. Nuralieva

Auto-generated profile, based on publicly available information

Galiya S. Nuralieva

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
SASergey Avdeev
Sergey Avdeev
GNG. S. Nuralieva
G. S. Nuralieva
VGV. V. Gainitdinova
V. V. Gainitdinova
GBG. E. Baimakanova
G. E. Baimakanova
ASA. K. So
A. K. So
БЕБаймаканова Гульсара Евсингильдеевна
Баймаканова Гульсара Евсингильдеевна
Aim. To evaluate the efficacy of mechanical bacterial lysate on the prevention of infectious exacerbations of chronic obstructive pulmonary disease in patients with frequent exacerbations. Materials and methods. The study included patients (n=60) with frequent exacerbations of COPD (groups C and D according to the GOLD classification). All COPD patients were divided into two groups by blind method. The first group (n=30) received conventional therapy for COPD plus MBL (the course included 3 cycles of 10 days therapy with 20-day intervals between them). The second group of patients (control, n=30) received conventional therapy for COPD without MBL.We evaluated the severity of symptoms, frequency of recurrence of COPD exacerbations, readmissions, need for emergency care and changes in basic therapy of COPD. Evaluations were done on 10 days, 1, 3 and 6 months from the start of the study. Results. Adding of MBL to the therapy list of COPD resulted in a significant decrease of biomarkers of systemic inflammation and sputum purulence during compared to the control group. After 6 months of observation MBL group demonstrated statistically significant improvement of respiratory function, decrease in frequency of COPD exacerbations, needs for emergency medical service, reduced changes in basic therapy and hospitalization for exacerbation of COPD. Therapy with MBL showed a high degree of safety and low incidence of adverse events. Conclusion. The results of the study indicate that MBL may be used for the prevention of severe infectious exacerbations of COPD.

1 October 2022 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
AYAndrey Yaroshetskiy
Andrey Yaroshetskiy
ZMZamira M. Merzhoeva
Zamira M. Merzhoeva
NTNatalia A. Tsareva
Natalia A. Tsareva
НТНаталья Трушенко
Наталья Трушенко
GNGalia S. Nuralieva
Galia S. Nuralieva
SASergey Avdeev
Sergey Avdeev
Background: Data on the efficacy of non-invasive ventilation (NIV) after progression of respiratory failure in patients who have already received oxygen therapy, or CPAP outside ICU is limited. The study aimed to find predictors of NIV failure based on breathing pattern, gas exchange, and accessory respiratory muscles evaluation in patients who progressed to moderate-to-severe COVID-19 ARDS. Methods: This was a prospective observational study in patients with moderate-to-severe COVID-19-ARDS on NIV (n = 80) admitted to COVID-ICU of Sechenov University. The combined success rate for conventional oxygen and CPAP outside ICU was 78.6% (440 of 560 patients). The primary endpoints were intubation rate and mortality. We measured respiratory rate, exhaled tidal volume (Vte), mean peak inspiratory flow (PIF), inspiratory time (Ti), PaO2, SpO2, end-tidal carbon dioxide (PETCO2), and Patrick score, and calculated ROX index, PaO2/FiO2, ventilatory ratio, and alveolar dead space (Vdalv/Vt) on Days 1, 3, 5, 7, 10, and 14. For all significant differences between NIV success and failure groups in measured data, we performed ROC analysis. Results: NIV failure rate in ICU after deterioration of respiratory failure outside ICU was 71.3% (n = 57). Patients with the subsequent NIV failure were older at inclusion, more frail, had longer duration of disease before ICU admission, and higher rate of CPAP use outside ICU. ROC-analysis revealed that the following respiratory parameters after 48 h of NIV can serve as a predictors for NIV failure in moderate-to-severe COVID-19-associated ARDS: PaO2/FiO2 < 112 mmHg (AUROC 0.90 (0.93–0.97), p < 0.0001); PETCO2 < 19.5 mmHg (AUROC 0.84 (0.73–0.94), p < 0.0001); VDalv/VT > 0.43 (AUROC 0.78 (0.68–0.90), p < 0.0001); ROX-index < 5.02 (AUROC 0.89 (0.81–0.97), p < 0.0001); Patrick score > 2 points (AUROC 0.87 (0.78–0.96), p = 0.006). Conclusion: In patients who progressed to moderate-to-severe COVID-19-ARDS probability of NIV success rate was about 1/3. Prediction of the NIV failure can be made after 48 h based on ROX index < 5.02, PaO2/FiO2 < 112 mmHg, PETCO2 < 19.5 mmHg, and Patrick score > = 2. Trial registration: ClinicalTrials.gov identifier: NCT04667923, registered on 16/12/2020.

15 November 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
PGP. V. Glybochko
P. V. Glybochko
VFV. V. Fomin
V. V. Fomin
SMS. V. Moiseev
S. V. Moiseev
SASergey Avdeev
Sergey Avdeev
AYA. G. Yavorovskiy
A. G. Yavorovskiy
ЯАЯковлева Александра Андреевна
Яковлева Александра Андреевна
Aim. In a retrospective study, we evaluated factors associated with the early development of septic shock in patients with severe COVID-19. Materials and methods. We collected medical records of the intensive care unit patients submitted by the local COVID-19 hospitals across Russia to the Federal Center for the Critical Care at the Sechenov First Moscow State Medical University (Sechenov University). Septic shock in crticially ill patients requiring mechanical ventilation was defined as a need in vasopressors to maintain blood pressure. Results. We studied 1078 patients with severe COVID-19 who were admitted to the intensive care units for respiratory support. There were 611 males and 467 females. The mean age was 61.013.7 years. Five hundred twenty five medical records (48.7%) were received from the Moscow hospitals, 159 (14.7%) from the Moscow region, and 394 (36.5%) from the hospitals located in 58 regions of the Russian Federation. In 613 (56.9%) patients, diagnosis of SARS-CoV-2 infection was confirmed by PCR, and in the other cases it was established on the basis of the clinical picture and the results of the chest CT scan. Septic shock developed in 214 (19.9%) of 1078 patients. In the logistic regression model, the risk of septic shock in patients older than 50 years was higher than in patients of a younger age (OR 2.34; 95% CI 1.533.67; p0.0001). In patients with more severe SARS-CoV-2 infection, there was an increase in the prevalence of cardiovascular diseases, including coronary heart disease and atrial fibrillation, type 2 diabetes and malignant tumors. The risk of septic shock in patients with three or more concomitant diseases was higher than in patients without any concomitant chronic diseases (OR 1.76; 95% CI 1.762.70). Conclusion. The risk of septic shock in patients with acute respiratory distress syndrome induced by SARS-CoV-2 is higher in patients older than 50 years with concomitant diseases, although a severe course of the disease is also possible in younger patients without any concomitant disorders.

22 October 2025 in Journal of Respiratory Medicine
Verified
Journal Article
Closed access
PDF file
SASergey Avdeev
Sergey Avdeev
ADA.V. Dekhnich
A.V. Dekhnich
AZA.A. Zaytsev
A.A. Zaytsev
Roman KozlovRoman Kozlov
Roman Kozlov
ILIgor Leshchenko
Igor Leshchenko
ASAnna Shmidt
Anna Shmidt
The article presents a short version of the clinical guidelines «Community-Acquired Pneumonia in Adults 2024», developed by the Russian Respiratory Society, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy, approved by the Ministry of Health of the Russian Federation.

15 May 2024 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
SASergey Avdeev
Sergey Avdeev
ILIgor Leshchenko
Igor Leshchenko
GIGalina G. L. Ignatova
Galina G. L. Ignatova
VAVladimir Antonov
Vladimir Antonov
NKN. E. Kostina
N. E. Kostina
ETE. L. Tikhonovich
E. L. Tikhonovich
According to the literature, the risk of death in patients with chronic obstructive pulmonary disease (COPD) increases with both frequency and severity of the disease exacerbations. However, the clinical burden and healthcare resource utilization associated with severe COPD exacerbations in the Russian population have not been adequately studied.The aim of this study was to assess the clinical burden of severe COPD in Russia by examining the relationship between frequency of severe exacerbations, clinical outcomes, and healthcare utilization among the Russian patients.Methods. The EXACOS International Study on Exacerbations and Outcomes was an observational, cross-sectional study that collected retrospective data from medical records over a five-year period. The study population included a broad range of COPD patients monitored by pulmonologists. The purpose of the study was to assess the frequency of severe exacerbations that were defined as hospitalizations (with or without admission to an intensive care unit) or emergency department visits due to worsening of COPD symptoms.Results. A total of 326 patients with COPD were included (mean age: 64.8 years, 87.1% male). Most participants had moderate (137 (42.0%)) or severe COPD (135 (41.4%)), as well as comorbidities (275 (84.4%)). The most common comorbidities included hypertension, heart failure, and diabetes. During the study period, 120 (40.0%), 158 (48.5%), and 247 (75.8%) patients received courses of oral corticosteroids, injectable corticosteroids and antibiotics, respectively. 250 (76.7%) patients experienced at least one severe COPD exacerbation, with a total of 1,026 events; and 102 (31.3%) had more than 3 exacerbations. The annual number of exacerbations increased from 128 in 2019 to 294 in 2021 (p < 0.0001), and the proportion of patients with severe exacerbations also increased from 23.6% in 2009 to 54.7% in 2021.Conclusion. The high clinical burden of severe COPD exacerbations among the Russian population indicates a significant need for further research into factors leading to these events, modification of these factors and optimization of therapy to prevent the exacerbations.

27 May 2024 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
NTN. A. Tsareva
N. A. Tsareva
GNGalina Nekludova
Galina Nekludova
AYAndrey Yaroshetskiy
Andrey Yaroshetskiy
GNG. S. Nuralieva
G. S. Nuralieva
FKF. T. Kurkieva
F. T. Kurkieva
SASergey Avdeev
Sergey Avdeev
For the first time, the effectiveness and safety of high doses of inhaled nitric oxide (iNO) in patients with community-acquired pneumonia (CAP) has been demonstrated.The aim of the study was to examine the effectiveness and safety of adding iNO to standard treatment for patients with CAP.Methods. A pilot, single-center, prospective, randomized, open-label clinical trial was conducted, which included patients (n = 120) hospitalized with CAP. Randomization was carried out using the blind envelope method. Patients in the main group (n = 60) received iNO through nasal cannulas using the Tianox iNO therapy device (AIT-NO-Ol according to TU 32.50. 21-001-07623615-2017) in addition to the therapy according to the standard of care at the study center. Inhalations were carried out with high doses of NO, namely 200 ppm for 15 minutes 3 times a day, regardless of food intake. Patients in the control group (n = 60) received only the therapy recommended by the standard of care at the study center. Clinical and laboratory parameters were assessed and safety of the therapy was monitored during the study.Results. No significant differences were identified between the main group and the control group in demographic, clinical, laboratory and instrumental data at baseline. Patients receiving iNO as an adjunct to standard therapy had a more significant improvement in clinical symptoms starting from the 3rd day and better oxygenation parameters on the 7th day of therapy. There was a more significant decrease in the level of C-reactive protein on the 5th and 7th days of therapy and a more significant decrease in the level of leukocytes on the 5th day in the main group. The duration of hospitalization in the main group was significantly shorter than that in the control group. NO inhalation was not associated with any side effects and was well tolerated.Conclusion. The use of high doses of NO has a positive effect on the clinical status, markers of inflammation, reduces the length of hospitalization, and demonstrates good tolerability and safety in patients with CAP.